Send to

Choose Destination
J Pharm Biomed Anal. 2012 Feb 5;59:123-9. doi: 10.1016/j.jpba.2011.10.016. Epub 2011 Oct 20.

Validated LC-MS/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic study.

Author information

Swiss BioAnalytics AG, Sternenfeldstrasse 14, 4127 Birsfelden, Switzerland.


A sensitive liquid chromatography-tandem mass spectrometry method has been developed to quantify miglustat in mouse plasma and in human plasma. The method involved simple protein precipitation with methanol. N-(n-nonyl)deoxynojirimycin was used as internal standard. Separation was performed on a Gemini C₁₈ column (2.1 mm × 50 mm, particle size 5 μm) with a binary gradient at a flow rate of 600 μl/min. The mobile phases were methanol and water both containing 0.01% of a 25% ammonium hydroxide solution. The triple stage quadrupole mass spectrometer was operated in APCI mode using the transitions m/z 220.1 ≥ 158.0 for miglustat and m/z 290.1 ≥ 228.0 for the internal standard. The method was linear over a range of 10-10,000 ng/ml. The intra-day coefficients of variation for mouse plasma were equal to or smaller than 14.1%. The intra- and inter-day accuracies were 84.5-107.2% and 90.9-104.0%, respectively. For human plasma the intra-day coefficients of variation were equal to or smaller than 13.5%, while accuracies ranged between 93.6% and 100.0%. The validated method offered increased sensitivity (10 times higher) and decreased cycle times compared to other methods. It was successfully applied to the pharmacokinetic assessment of miglustat during treatment of patients with cystic fibrosis.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center